Israeli company BiondVax, which is developing a universal influenza vaccine, is one of six companies to receive the prestigious Seventh Framework Program for Research (FP7) award. The six companies will receive a total of €6 million, €500,000 of which will be granted to BiondVax.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

UN Honors Israeli Food Exec For Sustainability Work
September 26, 2023

Startup Unveils Tech To Speed Up Growth Of Cultivated Meat
September 26, 2023

Israel Invests Millions To Help AI Comprehend Hebrew, Arabic
September 21, 2023

Cybersecurity Startup Cato Raises $238M With $3B Valuation
September 21, 2023
Facebook comments